{"pmid":32468014,"title":"Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).","text":["Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).","The major impact produced by the severe acute respiratory syndrome coronavirus 2 (SARSCoV2) focused many researchers attention to find treatments that can suppress transmission or ameliorate the disease. Despite the very fast and large flow of scientific data on possible treatment solutions, none have yet demonstrated unequivocal clinical utility against coronavirus disease 2019 (COVID19). This work represents an exhaustive and critical review of all available data on potential treatments for COVID19, highlighting their mechanistic characteristics and the strategy development rationale. Drug repurposing, also known as drug repositioning, and target based methods are the most used strategies to advance therapeutic solutions into clinical practice. Current in silico, in vitro and in vivo evidence regarding proposed treatments are summarized providing strong support for future research efforts.","Int J Mol Med","Nitulescu, George Mihai","Paunescu, Horia","Moschos, Sterghios A","Petrakis, Dimitrios","Nitulescu, Georgiana","Ion, George Nicolae Daniel","Spandidos, Demetrios A","Nikolouzakis, Taxiarchis Konstantinos","Drakoulis, Nikolaos","Tsatsakis, Aristidis","32468014"],"abstract":["The major impact produced by the severe acute respiratory syndrome coronavirus 2 (SARSCoV2) focused many researchers attention to find treatments that can suppress transmission or ameliorate the disease. Despite the very fast and large flow of scientific data on possible treatment solutions, none have yet demonstrated unequivocal clinical utility against coronavirus disease 2019 (COVID19). This work represents an exhaustive and critical review of all available data on potential treatments for COVID19, highlighting their mechanistic characteristics and the strategy development rationale. Drug repurposing, also known as drug repositioning, and target based methods are the most used strategies to advance therapeutic solutions into clinical practice. Current in silico, in vitro and in vivo evidence regarding proposed treatments are summarized providing strong support for future research efforts."],"journal":"Int J Mol Med","authors":["Nitulescu, George Mihai","Paunescu, Horia","Moschos, Sterghios A","Petrakis, Dimitrios","Nitulescu, Georgiana","Ion, George Nicolae Daniel","Spandidos, Demetrios A","Nikolouzakis, Taxiarchis Konstantinos","Drakoulis, Nikolaos","Tsatsakis, Aristidis"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468014","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3892/ijmm.2020.4608","topics":["Treatment"],"weight":1,"_version_":1668167110045466624,"score":9.490897,"similar":[{"pmid":32400323,"title":"In vitro data of current therapies for SARS-CoV-2.","text":["In vitro data of current therapies for SARS-CoV-2.","BACKGROUND: In December 2019, a new coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has emerged from China causing pneumonia outbreaks first in the Wuhan region and currently worldwide. In the light of the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the most efficient tool to find therapeutic solution. OBJECTIVES: The aim of this study was to summarize in vitro data of current agents used for the management of SARSCoV-2 all over the world. METHODS: A literature search of articles from January 2000 until April 2020 was performed using MEDLINE, EMBASE and the Cochrane Library to assess in vitro data of current or putative therapies for SARS-CoV-2. RESULTS: Although in vitro studies are scarce, data regarding chloroquine and hydroxychloroquine, remdesivir, nitazoxanide, teicoplanin, ivermectin, lopinavir, homoharringtonine and emetine seem promising. CONCLUSION: Scientist all over the world should work together and increase their efforts in order to find feasible and efficient solutions against this new global viral threat.","Curr Med Chem","Anastasiou, Ioanna A","Eleftheriadou, Ioanna","Tentolouris, Anastasios","Tsilingiris, Dimitrios","Tentolouris, Nikolaos","32400323"],"abstract":["BACKGROUND: In December 2019, a new coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has emerged from China causing pneumonia outbreaks first in the Wuhan region and currently worldwide. In the light of the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the most efficient tool to find therapeutic solution. OBJECTIVES: The aim of this study was to summarize in vitro data of current agents used for the management of SARSCoV-2 all over the world. METHODS: A literature search of articles from January 2000 until April 2020 was performed using MEDLINE, EMBASE and the Cochrane Library to assess in vitro data of current or putative therapies for SARS-CoV-2. RESULTS: Although in vitro studies are scarce, data regarding chloroquine and hydroxychloroquine, remdesivir, nitazoxanide, teicoplanin, ivermectin, lopinavir, homoharringtonine and emetine seem promising. CONCLUSION: Scientist all over the world should work together and increase their efforts in order to find feasible and efficient solutions against this new global viral threat."],"journal":"Curr Med Chem","authors":["Anastasiou, Ioanna A","Eleftheriadou, Ioanna","Tentolouris, Anastasios","Tsilingiris, Dimitrios","Tentolouris, Nikolaos"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400323","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.2174/0929867327666200513075430","keywords":["ace2 receptor.","sars-cov-2 (covid-19)","veroe6 cells","in vitro studies","therapies","vaccines"],"locations":["China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine","remdesivir","Chloroquine","Ivermectin","nitazoxanide","Homoharringtonine","Lopinavir","Teicoplanin","Emetine"],"topics":["Treatment"],"weight":1,"_version_":1666714494753046528,"score":147.94969},{"pmid":32430617,"title":"A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).","text":["A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the reason for this ongoing pandemic infection diseases termed coronavirus disease 2019 (COVID-19) that has emerged since early December 2019 in Wuhan City, Hubei Province, China. In this century, it is the worst threat to international health and the economy. After 4 months of COVID-19 outbreak, there is no certain and approved medicine against it. In this public health emergency, it makes sense to investigate the possible effects of old drugs and find drug repositioning that is efficient, economical, and riskless process. Old drugs that may be effective are from different pharmacological categories, antimalarials, anthelmintics, anti-protozoal, anti-HIVs, anti-influenza, anti-hepacivirus, antineoplastics, neutralizing antibodies, immunoglobulins, and interferons. In vitro, in vivo, or preliminary trials of these drugs in the treatment of COVID-19 have been encouraging, leading to new research projects and trials to find the best drug/s. In this review, we discuss the possible mechanisms of these drugs against COVID-19. Also, it should be mentioned that in this manuscript, we discuss preliminary rationales; however, clinical trial evidence is needed to prove them. COVID-19 therapy must be based on expert clinical experience and published literature and guidelines from major health organizations. Moreover, herein, we describe current evidence that may be changed in the future.","Naunyn Schmiedebergs Arch Pharmacol","Rameshrad, Maryam","Ghafoori, Majid","Mohammadpour, Amir Hooshang","Nayeri, Mohammad Javad Dehghan","Hosseinzadeh, Hossein","32430617"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the reason for this ongoing pandemic infection diseases termed coronavirus disease 2019 (COVID-19) that has emerged since early December 2019 in Wuhan City, Hubei Province, China. In this century, it is the worst threat to international health and the economy. After 4 months of COVID-19 outbreak, there is no certain and approved medicine against it. In this public health emergency, it makes sense to investigate the possible effects of old drugs and find drug repositioning that is efficient, economical, and riskless process. Old drugs that may be effective are from different pharmacological categories, antimalarials, anthelmintics, anti-protozoal, anti-HIVs, anti-influenza, anti-hepacivirus, antineoplastics, neutralizing antibodies, immunoglobulins, and interferons. In vitro, in vivo, or preliminary trials of these drugs in the treatment of COVID-19 have been encouraging, leading to new research projects and trials to find the best drug/s. In this review, we discuss the possible mechanisms of these drugs against COVID-19. Also, it should be mentioned that in this manuscript, we discuss preliminary rationales; however, clinical trial evidence is needed to prove them. COVID-19 therapy must be based on expert clinical experience and published literature and guidelines from major health organizations. Moreover, herein, we describe current evidence that may be changed in the future."],"journal":"Naunyn Schmiedebergs Arch Pharmacol","authors":["Rameshrad, Maryam","Ghafoori, Majid","Mohammadpour, Amir Hooshang","Nayeri, Mohammad Javad Dehghan","Hosseinzadeh, Hossein"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32430617","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s00210-020-01901-6","keywords":["covid-19","repositioning","sars-cov2","therapy"],"locations":["Wuhan","Hubei","China","vivo"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667342288216391680,"score":142.29724},{"pmid":32292689,"pmcid":"PMC7102550","title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","text":["Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.","Acta Pharm Sin B","Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua","32292689"],"abstract":["SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections."],"journal":"Acta Pharm Sin B","authors":["Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292689","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.apsb.2020.02.008","keywords":["3clpro, 3-chymotrypsin-like protease","drug repurposing","e, envelope","homology modeling","m, membrane protein","molecular docking","n, nucleocapsid protein","nsp, non-structure protein","orf, open reading frame","pdb, protein data bank","rdrp, rna-dependence rna polymerase","remdesivir","s, spike","sars-cov-2","sud, sars unique domain","ub, ubiquitin-like domain"],"topics":["Treatment"],"weight":1,"_version_":1666138494492213249,"score":141.98697},{"pmid":32259313,"title":"Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.","text":["Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.","The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacologic management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immunomodulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.","Pharmacotherapy","Barlow, Ashley","Landolf, Kaitlin M","Barlow, Brooke","Yeung, Siu Yan Amy","Heavner, Jason J","Claassen, Cassidy W","Heavner, Mojdeh S","32259313"],"abstract":["The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacologic management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immunomodulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic."],"journal":"Pharmacotherapy","authors":["Barlow, Ashley","Landolf, Kaitlin M","Barlow, Brooke","Yeung, Siu Yan Amy","Heavner, Jason J","Claassen, Cassidy W","Heavner, Mojdeh S"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259313","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/phar.2398","keywords":["antivirals","cytochrome p450","dialysis","infectious disease","liver","renal"],"locations":["vivo"],"topics":["Treatment"],"weight":1,"_version_":1666138493090267137,"score":127.2813},{"pmid":32117569,"pmcid":"PMC7029759","title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.","text":["Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.","A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).","F1000Res","Kruse, Robert L","32117569"],"abstract":["A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s)."],"journal":"F1000Res","authors":["Kruse, Robert L"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32117569","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.12688/f1000research.22211.2","keywords":["2019-ncov","ace2","wuhan","coronavirus","neutralizing antibody","outbreak"],"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Oligonucleotides"],"topics":["Treatment"],"weight":1,"_version_":1666138492834414592,"score":122.63779}]}